Fate Therapeutics Inc (NASDAQ:FATE) currently has a daily average trading volume of 2.05M but it saw 1422878 shares traded in last market. With a market cap of 151.31M USD, the company’s current market price of $1.32 came rising about 3.94 while comparing to the previous closing price of $1.27. In past 52 weeks, the stock remained buoying in the range of price level as high as $5.92 and as low as $0.66.
Piper Sandler upgraded its recommendation for the stock as a “Overweight” from “Neutral” on June 17, 2024 while assigning a price target range of $4-$6. Wells Fargo issued its recommendations for the stock as it resumed the price target for the stock is $6.
Over the week, FATE’s stock price is moving 12.82% up while it is 12.82% when we observe its performance for the past one month. Year-to-date it is -20.00% down and over the past year, the stock is showing a downside performance of -62.50%.
The company is expected to be releasing its next quarterly report in June, for which analysts forecasted an EPS of -0.34 while estimate for next year EPS is -1.26. In next quarter, company is expected to be making quarterly sales of $1.13M as analysts are expecting the sales for current fiscal year at $5.2M and seeing the company making $4.03M in sales next year. Moreover, analysts are in estimates of $1.12M for current-quarter revenue.
Currently, Fate Therapeutics Inc’s total number of outstanding shares is 114.60M with 1.74% of that held by the insiders while 94.28% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -48.16% and return on equity (ROE) at -49.23%. Stock’s beta reads 2.26. Stock has a price to book (P/B) ratio of 0.52 while price to sale or P/S ratio amounts to 11.34. Its return on asset (ROA) is -36.32% on average.
